Colorectal Cancer Clinical Trials in Austin

Showing 101-120 of 260 trials

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

NCT05563272

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Cervical CancerColorectal CancerEsophageal Cancer+16 more

Telix Pharmaceuticals (Innovations) Pty Ltd11 participantsStarted Jun 2023

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +7 more locations

RECRUITING< 1 mile

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

NCT06620627

The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.

Colorectal Cancer Screening

Natera, Inc.5,000 participantsStarted Jan 2024

Austin, Texas, United States

COMPLETEDPhase 1/274 miles

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

NCT04616196

This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).

Head and Neck Squamous Cell CarcinomaColorectal Cancer

Nektar Therapeutics25 participantsStarted Oct 2020

San Diego, California, United States • San Francisco, California, United States • Minneapolis, Minnesota, United States +3 more locations

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Colorectal Cancer Trials in Other Cities

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Phase 2 Study of DKN-01 in Colorectal Cancer

ColoCare Study - Colorectal Cancer Cohort

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Other Conditions in Austin